Biotech entity
Genomics Aotearoa is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 9-day span, the pace is roughly 1.6 stories per week. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: Mar 15, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Genomics Aotearoa is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 9-day span, the pace is roughly 1.6 stories per week. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. Their average consequence score of 6.5 runs above the beat's 6.1 for that window. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Biotech stories that mention New Zealand Government, published between March 10, 2026 and March 18, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 131 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering New Zealand Government. Shared-story counts are live from our verified record — not editorial picks.
Interim Review
Assessment of clinical utility and cost-effectiveness for long-term funding.
Policy Implementation
Expected legislative changes based on the inquiry's recommendations.
Trial Launch
Official commencement of patient recruitment for cancer and rare disorder cohorts.
Phase Two Findings
Release of the 4 main lessons for future pandemic resilience and institutional reform.
Data Integration
First wave of genomic data integrated into clinical health records for treatment matching.
Infrastructure Setup
Accreditation of local laboratories and installation of high-throughput sequencers.
Phase One Report
Focus on immediate response measures, lockdowns, and initial vaccine procurement.
Inquiry Commencement
The Royal Commission of Inquiry into COVID-19 Lessons officially begins.
New Zealand has initiated a major genomic medicine trial designed to provide locally-based genetic sequencing for patients battling cancer and rare diseases. By repatriating diagnostic capabilities, the program aims to accelerate treatment timelines and improve health equity across the country's diverse populations.
The second phase of New Zealand’s COVID-19 inquiry has identified four pivotal pillars to bolster future pandemic resilience, focusing on institutional reform and equitable health outcomes. These findings provide a blueprint for structural changes in how the nation manages biological threats and pharmaceutical supply chains.
New Zealand Government is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
